Compare Stocks: IRD, MESO, STOK, and BHVN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHVN Biohaven	$13.58 -2.3%	$14.41	$7.48 ▼ $18.57	$2.10B	1.28	3.67 million shs	6.43 million shs
IRD Opus Genetics	$5.18 -1.9%	$4.04	$1.42 ▼ $7.07	$436.38M	0.58	4.75 million shs	5.54 million shs
MESO Mesoblast	$15.13 +1.7%	$16.18	$13.05 ▼ $21.50	$1.93B	2.12	182,560 shs	214,720 shs
STOK Stoke Therapeutics	$28.43 -1.7%	$30.49	$20.32 ▼ $40.22	$1.87B	1.23	730,686 shs	1.56 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHVN Biohaven	+14.96%	+8.28%	+1.80%	+1.99%	-5.90%
IRD Opus Genetics	-2.40%	-13.01%	+43.09%	+29.73%	+269.23%
MESO Mesoblast	+3.19%	-4.06%	-10.80%	+3.48%	-1.33%
STOK Stoke Therapeutics	+3.65%	-1.40%	-9.99%	-6.68%	+27.22%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHVN Biohaven	$13.58 -2.3%	$14.41	$7.48 ▼ $18.57	$2.10B	1.28	3.67 million shs	6.43 million shs
IRD Opus Genetics	$5.18 -1.9%	$4.04	$1.42 ▼ $7.07	$436.38M	0.58	4.75 million shs	5.54 million shs
MESO Mesoblast	$15.13 +1.7%	$16.18	$13.05 ▼ $21.50	$1.93B	2.12	182,560 shs	214,720 shs
STOK Stoke Therapeutics	$28.43 -1.7%	$30.49	$20.32 ▼ $40.22	$1.87B	1.23	730,686 shs	1.56 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHVN Biohaven	+14.96%	+8.28%	+1.80%	+1.99%	-5.90%
IRD Opus Genetics	-2.40%	-13.01%	+43.09%	+29.73%	+269.23%
MESO Mesoblast	+3.19%	-4.06%	-10.80%	+3.48%	-1.33%
STOK Stoke Therapeutics	+3.65%	-1.40%	-9.99%	-6.68%	+27.22%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHVN Biohaven	2.59	Moderate Buy	$18.69	36.23% Upside
IRD Opus Genetics	2.89	Moderate Buy	$11.92	131.74% Upside
MESO Mesoblast	2.00	Hold	$39.00	157.97% Upside
STOK Stoke Therapeutics	2.82	Moderate Buy	$44.25	55.95% Upside

Current Analyst Ratings Breakdown

Latest IRD, MESO, STOK, and BHVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	BHVN Biohaven	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/10/2026	STOK Stoke Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/10/2026	BHVN Biohaven	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$10.00
9/10/2026	IRD Opus Genetics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$10.00 ➝ $13.00
9/9/2026	IRD Opus Genetics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$13.00 ➝ $16.00
9/9/2026	IRD Opus Genetics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$10.00 ➝ $20.00
9/9/2026	IRD Opus Genetics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
9/9/2026	IRD Opus Genetics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
9/9/2026	IRD Opus Genetics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
9/8/2026	BHVN Biohaven	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$23.00 ➝ $19.00
8/28/2026	BHVN Biohaven	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.39 per share	N/A
IRD Opus Genetics	$14.20M	29.95	N/A	N/A	$0.22 per share	23.39
MESO Mesoblast	$120.25M	16.33	N/A	N/A	$4.38 per share	3.45
STOK Stoke Therapeutics	$184.42M	9.93	N/A	N/A	$6.17 per share	4.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHVN Biohaven	-$738.82M	-$4.64	N/A	N/A	N/A	N/A	-1,328.94%	-138.27%	11/9/2026 (Estimated)
IRD Opus Genetics	-$49.59M	-$1.35	N/A	N/A	N/A	-1,091.82%	-338.88%	-150.13%	11/11/2026 (Estimated)
MESO Mesoblast	-$57.50M	-$0.28	N/A	41.99	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	-$6.89M	-$3.34	N/A	N/A	N/A	-753.60%	-59.36%	-51.46%	11/3/2026 (Estimated)

Latest IRD, MESO, STOK, and BHVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	-$0.91	-$0.1490	-$0.91	$0.49 million	N/A
8/6/2026	Q2 2026	IRD Opus Genetics	-$0.1567	-$0.14	+$0.0167	-$0.14	$2.63 million	$0.76 million
8/3/2026	Q2 2026	STOK Stoke Therapeutics	-$0.7950	-$0.93	-$0.1350	-$0.93	$4.89 million	$9.33 million
7/31/2026	Q4 2026	MESO Mesoblast	N/A	-$0.0660	N/A	-$0.0660	N/A	$34.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHVN Biohaven	21.23	4.73	4.73
IRD Opus Genetics	N/A	12.19	12.19
MESO Mesoblast	0.19	2.43	2.09
STOK Stoke Therapeutics	N/A	7.69	7.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHVN Biohaven	88.78%
IRD Opus Genetics	14.97%
MESO Mesoblast	1.43%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
BHVN Biohaven	13.80%
IRD Opus Genetics	11.70%
MESO Mesoblast	18.80%
STOK Stoke Therapeutics	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHVN Biohaven	274	151.04 million	130.20 million	Optionable
IRD Opus Genetics	28	82.65 million	72.98 million	N/A
MESO Mesoblast	108	129.88 million	105.46 million	Optionable
STOK Stoke Therapeutics	170	64.53 million	58.33 million	Optionable

IRD, MESO, STOK, and BHVN Headlines

Recent News About These Companies

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - September 16, 2026

September 17 at 8:01 AM | biospace.comB

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

September 16 at 4:01 PM | businesswire.com

Legal & General Group Plc Makes New Investment in Stoke Therapeutics, Inc. $STOK

September 8, 2026 | marketbeat.com

Stoke Therapeutics, Inc. $STOK Shares Sold by Troluce Capital Advisors LLC

September 6, 2026 | marketbeat.com

Bank of New York Mellon Corp Makes New Investment in Stoke Therapeutics, Inc. $STOK

September 5, 2026 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Insider Sells 5,545 Shares of Stock

September 4, 2026 | insidertrades.com

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of ...

September 3, 2026 | markets.businessinsider.com

Stoke Therapeutics (NASDAQ:STOK) Insider Sells $170,065.15 in Stock

September 3, 2026 | marketbeat.com

Stoke, Biogen report four-year zorevunersen data showing sustained seizure control

September 3, 2026 | ijr.comI

The Manufacturers Life Insurance Company Makes New Investment in Stoke Therapeutics, Inc. $STOK

September 3, 2026 | marketbeat.com

Stoke Therapeutics, Inc. $STOK Shares Acquired by Wellington Management Group LLP

September 2, 2026 | marketbeat.com

Stoke Therapeutics Inc 0GT

September 1, 2026 | morningstar.comM

Stoke Therapeutics and Biogen to present four-year zorevunersen data at epilepsy congress

September 1, 2026 | msn.com

57,784 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Deutsche Bank AG

August 29, 2026 | marketbeat.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of "Moderate Buy" from Analysts

August 29, 2026 | marketbeat.com

84,631 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Palo Alto Investors LP

August 28, 2026 | marketbeat.com

Jupiter Topco LLC Takes $59.36 Million Position in Stoke Therapeutics, Inc. $STOK

August 28, 2026 | marketbeat.com

BlackRock Inc. Buys Shares of 5,877,357 Stoke Therapeutics, Inc. $STOK

August 28, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Takes Position in Stoke Therapeutics, Inc. $STOK

August 25, 2026 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Earns Overweight Rating from Analysts at JPMorgan Chase & Co.

August 21, 2026 | marketbeat.com

Stoke Therapeutics shares rise as JPMorgan starts coverage with Overweight rating

August 21, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IRD, MESO, STOK, and BHVN Company Descriptions

Biohaven NYSE:BHVN

$13.58 -0.31 (-2.26%)

Closing price 03:59 PM Eastern

Extended Trading

$13.40 -0.17 (-1.26%)

As of 07:30 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Opus Genetics NASDAQ:IRD

$5.18 -0.10 (-1.89%)

Closing price 04:00 PM Eastern

Extended Trading

$5.24 +0.07 (+1.25%)

As of 07:53 PM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

Mesoblast NASDAQ:MESO

$15.13 +0.26 (+1.75%)

Closing price 04:00 PM Eastern

Extended Trading

$15.12 -0.01 (-0.07%)

As of 07:44 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Stoke Therapeutics NASDAQ:STOK

$28.43 -0.50 (-1.73%)

Closing price 04:00 PM Eastern

Extended Trading

$28.43 0.00 (0.00%)

As of 07:30 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IRD, MESO, STOK, and BHVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IRD, MESO, STOK, and BHVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IRD, MESO, STOK, and BHVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IRD, MESO, STOK, and BHVN Company Descriptions

Biohaven NYSE:BHVN

Opus Genetics NASDAQ:IRD

Mesoblast NASDAQ:MESO

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IRD, MESO, STOK, and BHVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IRD, MESO, STOK, and BHVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IRD, MESO, STOK, and BHVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IRD, MESO, STOK, and BHVN Company Descriptions

Biohaven NYSE:BHVN

Opus Genetics NASDAQ:IRD

Mesoblast NASDAQ:MESO

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools